share_log

Baird Initiates Coverage On Neurogene With Outperform Rating, Announces Price Target of $54

Baird Initiates Coverage On Neurogene With Outperform Rating, Announces Price Target of $54

贝尔德初始覆盖神经基因公司,给予跑赢大市评级,宣布54美元的目标价格。
Benzinga ·  06/11 05:18

Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $54.

贝尔德分析师Joel Beatty对Neurogene(纳斯达克股票代码:NGNE)进行了覆盖,给予跑赢市场评级,并宣布价格目标为54美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发